New York State Common Retirement Fund Trims Stake in United Therapeutics Co. (NASDAQ:UTHR)

New York State Common Retirement Fund decreased its position in shares of United Therapeutics Co. (NASDAQ:UTHRGet Rating) by 2.2% during the first quarter, according to its most recent filing with the SEC. The firm owned 86,813 shares of the biotechnology company’s stock after selling 1,939 shares during the period. New York State Common Retirement Fund owned about 0.19% of United Therapeutics worth $15,575,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Northwestern Mutual Investment Management Company LLC grew its holdings in shares of United Therapeutics by 0.7% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 7,466 shares of the biotechnology company’s stock worth $1,613,000 after acquiring an additional 50 shares during the period. Advisor Partners LLC grew its stake in shares of United Therapeutics by 4.4% in the 4th quarter. Advisor Partners LLC now owns 1,249 shares of the biotechnology company’s stock worth $270,000 after buying an additional 53 shares during the last quarter. CIBC Asset Management Inc grew its stake in shares of United Therapeutics by 3.0% in the 4th quarter. CIBC Asset Management Inc now owns 1,871 shares of the biotechnology company’s stock worth $404,000 after buying an additional 55 shares during the last quarter. NorthCrest Asset Manangement LLC grew its stake in shares of United Therapeutics by 1.5% in the 1st quarter. NorthCrest Asset Manangement LLC now owns 5,335 shares of the biotechnology company’s stock worth $957,000 after buying an additional 80 shares during the last quarter. Finally, Exchange Traded Concepts LLC grew its stake in shares of United Therapeutics by 3.0% in the 1st quarter. Exchange Traded Concepts LLC now owns 2,919 shares of the biotechnology company’s stock worth $524,000 after buying an additional 86 shares during the last quarter. Hedge funds and other institutional investors own 94.68% of the company’s stock.

Insider Activity

In other news, EVP Paul A. Mahon sold 4,552 shares of the stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $225.81, for a total transaction of $1,027,887.12. Following the transaction, the executive vice president now directly owns 36,397 shares of the company’s stock, valued at approximately $8,218,806.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, EVP Paul A. Mahon sold 4,552 shares of the firm’s stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $225.81, for a total value of $1,027,887.12. Following the transaction, the executive vice president now directly owns 36,397 shares of the company’s stock, valued at approximately $8,218,806.57. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Raymond Dwek sold 2,160 shares of the firm’s stock in a transaction on Monday, July 11th. The stock was sold at an average price of $241.29, for a total value of $521,186.40. The disclosure for this sale can be found here. Insiders have sold 52,712 shares of company stock valued at $11,740,574 in the last ninety days. 12.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts recently weighed in on UTHR shares. Wedbush upped their price target on United Therapeutics from $236.00 to $263.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 24th. Credit Suisse Group upped their price target on United Therapeutics from $219.00 to $247.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 24th. Jefferies Financial Group upped their price target on United Therapeutics from $223.00 to $245.00 in a research note on Tuesday, May 24th. JPMorgan Chase & Co. upped their price target on United Therapeutics from $225.00 to $238.00 in a research note on Tuesday, May 24th. Finally, Oppenheimer increased their target price on United Therapeutics from $275.00 to $300.00 in a research note on Thursday, May 5th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $250.14.

United Therapeutics Price Performance

NASDAQ UTHR opened at $221.65 on Friday. The business’s fifty day moving average price is $230.64 and its 200-day moving average price is $203.12. The stock has a market capitalization of $10.04 billion, a price-to-earnings ratio of 16.78, a PEG ratio of 4.22 and a beta of 0.53. The company has a debt-to-equity ratio of 0.19, a current ratio of 8.84 and a quick ratio of 8.54. United Therapeutics Co. has a 1-year low of $158.38 and a 1-year high of $245.48.

United Therapeutics (NASDAQ:UTHRGet Rating) last released its quarterly earnings results on Wednesday, August 3rd. The biotechnology company reported $2.41 earnings per share for the quarter, missing the consensus estimate of $4.10 by ($1.69). The firm had revenue of $466.90 million for the quarter, compared to the consensus estimate of $461.06 million. United Therapeutics had a net margin of 35.27% and a return on equity of 15.82%. United Therapeutics’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the company earned $3.65 earnings per share. On average, equities analysts predict that United Therapeutics Co. will post 17.19 earnings per share for the current year.

United Therapeutics Profile

(Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Read More

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHRGet Rating).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.